Caricamento...
Characteristics and outcomes of patients with type 2 diabetes mellitus treated with canagliflozin: a real-world analysis
BACKGROUND: Canagliflozin, an oral agent that inhibits sodium glucose co-transporter 2, improves glycemic control, body weight, and blood pressure and is generally well tolerated in patients with type 2 diabetes mellitus (T2DM). This study extends the scope of previous analyses by evaluating outcome...
Salvato in:
| Pubblicato in: | BMC Endocr Disord |
|---|---|
| Autori principali: | , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
BioMed Central
2015
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4630836/ https://ncbi.nlm.nih.gov/pubmed/26527413 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12902-015-0064-8 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|